Urethritis secondary prevention

Jump to navigation Jump to search

Urinary Tract Infections Main Page

Sexually Transmitted Diseases Main Page

Urethritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Urethritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Urethritis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Urethritis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onUrethritis secondary prevention

CDC onUrethritis secondary prevention

Urethritis secondary preventionin the news

Blogs onUrethritis secondary prevention

Directions to Hospitals Treating Urethritis

Risk calculators and risk factors for Urethritis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

In order to prevent transmission to one's partner and decrease the risk of antibiotic resistance, all patients must be instructed in safe sex practices and screening requirements after treatment.

Secondary Prevention

  • Patients should be instructed in safe sex practices.
  • All sex partners with whom a patient has engaged within the last 60 days must be evaluated for possible urethritis.
  • Patients should be screened for other sexually transmitted diseases e.g. HIV and syphilis.
  • All patients must be retested 3 months after treatment to evaluate the risk of resistance
  • Prophylactic ocular antimicrobial medication is strongly recommended for all newborns exposed to Neisseria gonorrhoeae during birth
  • Gonorrhea and chlamydia are reportable diseases per the CDC, and practitioners should contact their local state health department.[1][2][3]

References

  1. Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 9781455748013.
  2. Workowski KA, Bolan GA (2015). "Sexually transmitted diseases treatment guidelines, 2015". MMWR Recomm Rep. 64 (RR-03): 1–137. PMID 26042815.
  3. Brill JR (2010). "Diagnosis and treatment of urethritis in men". Am Fam Physician. 81 (7): 873–8. PMID 20353145.

Template:WH Template:WS